Cardiovascular complications arising from cancer therapy represent a growing clinical challenge as survival rates improve. While modern chemotherapeutic regimens have dramatically increased life expectancy for patients with malignancies such as breast cancer, lymphoma, and sarcoma, a subset of these treatments—particularly those classified as cardiotoxic—can compromise long-term cardiac function. Understanding how these drugs affect the heart is essential for oncologists and cardiologists to balance treatment efficacy with cardiovascular safety. Simulation techniques have emerged as powerful tools to predict, quantify, and mitigate cardiotoxic effects, offering a pathway toward personalized therapy that minimizes heart damage while maximizing antitumor benefit.

Scope of Cardiotoxicity in Oncology

Cardiotoxicity encompasses a spectrum of adverse cardiac events ranging from asymptomatic subclinical myocardial injury to overt heart failure. The incidence varies depending on the drug, cumulative dose, patient comorbidities, and genetic predisposition. For example, anthracycline-induced cardiomyopathy can occur in up to 5–26% of patients receiving high cumulative doses, while trastuzumab-related cardiac dysfunction is often reversible but requires careful monitoring. The challenge is not only acute toxicity but also delayed effects that may manifest years after treatment completion, underscoring the need for predictive models that extend beyond the immediate treatment window.

Defining Cardiotoxic Drugs

Cardiotoxic agents are broadly categorized by their primary mechanism of cardiac injury. Anthracyclines (doxorubicin, epirubicin) generate reactive oxygen species and interfere with topoisomerase IIβ in cardiomyocytes, leading to myofibrillar loss and mitochondrial dysfunction. Monoclonal antibodies like trastuzumab inhibit HER2 signaling, which is critical for cardiomyocyte survival and repair. Tyrosine kinase inhibitors (e.g., sunitinib, ponatinib) can induce hypertension, thromboembolism, and left ventricular dysfunction via off-target effects on vascular endothelial growth factor receptors. Additionally, proteasome inhibitors (carfilzomib), immune checkpoint inhibitors, and radiation therapy contribute to the multifaceted landscape of cancer therapy–related cardiac dysfunction.

Clinical Monitoring of Cardiac Function

Current guidelines recommend baseline cardiac assessment before initiating potentially cardiotoxic therapy, followed by periodic monitoring during and after treatment. Traditional methods include echocardiography (particularly assessment of left ventricular ejection fraction, LVEF) and serum biomarkers such as high-sensitivity troponin and natriuretic peptides. However, LVEF changes are often late markers of injury, and by the time a decline is detected, irreversible damage may have already occurred. This limitation has spurred interest in more sensitive imaging modalities like global longitudinal strain (GLS) and advanced biomarkers, as well as the integration of simulation models that can forecast subclinical dysfunction before it becomes clinically apparent.

Role of Simulation in Studying Cardiotoxic Effects

Simulation offers a controlled, ethical, and reproducible environment to explore the complex interactions between anticancer drugs and cardiac physiology. By leveraging mathematical and computational models, researchers can test hundreds of drug concentrations, dosing schedules, and patient-specific variables without exposing patients to harm. Simulations also allow the exploration of rare or extreme scenarios—such as drug interactions or pre-existing cardiac conditions—that would be difficult to study in clinical trials due to ethical constraints or sample size limitations.

Computational Models of Cardiac Electrophysiology

These models simulate ion channel dynamics, action potential propagation, and electrocardiographic changes in response to drug-induced modifications. For instance, drugs that block the hERG potassium channel can prolong the QT interval, increasing the risk of torsade de pointes. Computational electrophysiology models incorporate detailed cell‑level data (e.g., ion channel kinetics, intracellular calcium handling) to predict proarrhythmic risk. Such models have been validated against clinical ECG data and are now being used in early drug development screening by pharmaceutical companies and regulatory agencies.

Mechanical and Structural Models

Beyond electrical activity, cardiotoxic drugs also impair cardiac mechanics—contraction, relaxation, and wall motion. Finite element models of ventricular mechanics can simulate changes in tissue stiffness, contractile force, and strain patterns after drug exposure. These models often rely on patient-specific imaging data (from MRI or 3D echocardiography) and incorporate material properties of healthy versus stressed myocardium. By altering parameters such as myocyte contractility or extracellular matrix stiffness, researchers can predict how a particular drug regimen will affect global heart function, including ejection fraction and diastolic filling.

Integrated Multiscale Models

To capture the full complexity of the heart’s response, integrated models combine electrical, mechanical, and even metabolic pathways. These multiscale simulations link molecular-level drug effects to tissue-level function and whole-organ performance. For example, a model might incorporate drug-induced changes in mitochondrial respiration, which then feed into ATP availability, affecting cross-bridge cycling and sarcomere shortening. Such holistic approaches are computationally intensive but offer the most realistic representation of cardiotoxicity mechanisms.

Data Inputs Required for Credible Simulations

Simulation accuracy hinges on the quality and granularity of input data. Essential datasets include:

  • Drug-specific parameters: pharmacokinetics (dose, half-life, metabolite activity), binding affinities, and known off-target effects from in vitro and in vivo studies.
  • Patient characteristics: age, sex, body surface area, baseline cardiac function, comorbidities (hypertension, diabetes), and prior cardiotoxic exposures (e.g., chest radiation).
  • Cellular and molecular data: ion channel expression profiles, cardiomyocyte contractility indices, mitochondrial function metrics, and gene expression signatures related to oxidative stress or apoptosis.
  • Imaging data: high-resolution cardiac MRI, CT, or 3D echocardiography to define geometry, wall thickness, and regional deformation.
  • Longitudinal clinical outcomes: serial LVEF measurements, biomarker trajectories, and adverse cardiac events for model training and validation.

Model Validation Against Real-World Data

Simulation models must be rigorously validated before they can inform clinical decisions. This involves comparing model predictions against independent patient cohorts not used in model development. Metrics such as area under the receiver operating characteristic curve (AUC-ROC), sensitivity, and specificity for detecting cardiotoxicity are calculated. Prospective validation studies are especially valuable, as they test the model’s performance in real-time clinical settings. For instance, a computational model predicting LVEF decline in breast cancer patients receiving trastuzumab was validated against data from the SAFE-HEaRt trial, demonstrating an AUC above 0.80 after incorporating patient-specific imaging features.

Implications for Patient Care

The ultimate goal of cardiotoxicity simulation is to translate predictive insights into actionable clinical strategies. Below are key areas where modeling already influences or promises to transform patient management.

Risk Stratification and Personalized Monitoring

By integrating patient-specific data, simulation models can stratify individuals into low-, intermediate-, and high-risk categories for developing significant cardiac dysfunction. High-risk patients might be triaged to more frequent imaging (e.g., echocardiography every 3 months instead of every 6–12 months) or to early cardiology consultation. Conversely, low-risk patients could follow standard guidelines, reducing unnecessary testing and patient anxiety. A simulation study by Liang et al. (2024) demonstrated that a computational model incorporating genetic variants in RARG and NCF4 significantly improved risk prediction for anthracycline-induced cardiomyopathy compared to clinical factors alone.

Guiding Cardioprotective Interventions

Simulations can explore the timing and efficacy of cardioprotective agents such as dexrazoxane, beta-blockers, or angiotensin-converting enzyme inhibitors. For instance, a model might simulate whether starting a low-dose metoprolol at the same time as doxorubicin would attenuate LVEF decline more than waiting until after treatment. Studies using mechanistic models have shown that early β-blockade can mitigate contractile dysfunction by reducing oxidative stress and improving mitochondrial efficiency, but the benefit depends on patient-specific factors like baseline heart rate and blood pressure. Simulation allows these complexities to be disentangled before designing costly clinical trials.

Optimizing Chemotherapy Regimens

Simulations can inform dose adjustments and schedule modifications to reduce cumulative risk. For example, a model might predict that administering doxorubicin via continuous infusion rather than bolus injection lowers peak plasma concentration and subsequent myocardial injury, or that spacing doses further apart allows recovery of cardiomyocyte repair mechanisms. Additionally, simulations help evaluate alternative formulations—such as liposomal doxorubicin, which is designed to reduce cardiac exposure—by modeling drug distribution and clearance patterns. These insights are especially valuable for patients who require high cumulative doses or have pre-existing cardiac conditions.

Future Directions and Innovations

As computational power, data availability, and modeling techniques continue to advance, the field of cardiotoxicity simulation is poised for transformative progress.

Artificial Intelligence and Machine Learning

Machine learning algorithms can identify hidden patterns in large datasets (electronic health records, genomics, imaging) that traditional mechanistic models may miss. Hybrid approaches that combine mechanistic simulations with neural networks are emerging: the mechanistic component ensures biological plausibility, while the ML component improves prediction accuracy by capturing non-linear interactions and missing variables. For instance, a 2023 study in Circulation: Cardiovascular Imaging used a deep learning model trained on echocardiographic strain data to predict trastuzumab-related cardiotoxicity with 90% sensitivity at 6 months.

Multi-Omics Integration

Genomics, transcriptomics, proteomics, and metabolomics offer detailed molecular portraits of individual patient tumors and hearts. Integrating multi-omics data into simulation models can reveal patient-specific susceptibilities, such as polymorphisms affecting drug metabolism or DNA repair pathways. For example, variants in ABCB1 and UGT1A6 influence anthracycline clearance and may predispose certain patients to higher cardiac exposure. Simulation models that incorporate such genetic information can personalize recommendations for dose adjustment or alternative therapy selection.

Patient-Specific Digital Twins

Digital twin technology—a virtual replica of a patient’s cardiovascular system that updates in real time with clinical data—represents the apex of personalized medicine. A digital twin of the heart could simulate the effects of multiple drugs, lifestyle factors, and disease progression over a patient’s entire treatment trajectory. While still in early development, several research groups have demonstrated proof-of-concept digital twins for cardiotoxicity monitoring in preclinical models. A notable example is the Cardio-ONC platform reported in Nature Biomedical Engineering, which uses patient-specific imaging and pharmacokinetic data to predict cardiac function changes during chemotherapy and proposes personalized cardioprotective strategies.

In Vitro and In Vivo Simulation Synergy

Computational models are increasingly being combined with human-induced pluripotent stem cell–derived cardiomyocytes (iPSC-CMs) to create “hybrid” simulation platforms. iPSC-CMs from individual patients can be exposed to drugs in a dish, and the resulting contractile dysfunction or electrophysiological changes are used to parameterize a computational model. This approach captures patient-specific genetic and epigenetic factors while leveraging the scalability of computer simulations. For instance, the HiPSC-CM integrated model has been used to predict doxorubicin-induced cardiotoxicity with high accuracy and to test rescue strategies such as co-administration of antioxidants.

Challenges and Limitations

Despite their promise, simulation models face several barriers to widespread clinical adoption. First, data integration remains a major hurdle: patient records often lack standardized formatting, imaging protocols vary across institutions, and high-dimensional omics data are not routinely collected in oncology practice. Second, model complexity can lead to overfitting or computational intractability, particularly for multiscale simulations that attempt to span from molecular to whole-organ scales. Third, validation in diverse populations is often lacking; many models are developed using data from homogeneous clinical trial cohorts and may not generalize to patients from different ethnicities, age groups, or with multiple comorbidities. Fourth, regulatory and reimbursement pathways for decision-support tools are still evolving—clinical adoption will require clear evidence that simulation-guided care improves outcomes without increasing costs.

Conclusion

Simulation of cardiotoxic drug effects on heart function is transitioning from a research tool to a clinically relevant instrument that can aid in risk stratification, treatment planning, and monitoring optimization. By integrating patient-specific data from imaging, pharmacokinetics, and molecular profiling, these models offer a personalized pathway to balance the lifesaving benefits of chemotherapy against the risk of lasting cardiovascular damage. As computational and data science advances continue to refine model accuracy and usability, simulation is poised to become a standard component of cardio-oncology practice—ultimately improving survival and quality of life for the growing population of cancer survivors.